Don't miss new insights on Daromun in melanoma on Il Sole 24 Ore! https://lnkd.in/dUqwRP27
Philogen S.p.A.
Fabbricazione di prodotti farmaceutici
Sovicille, SIENA 20.968 follower
Innovating Targeting
Chi siamo
Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for the treatment of angiogenesis-related disorders. Angiogenesis, i.e. the formation of new blood vessels, is a characteristic feature of many severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. The company has been a pioneer in the isolation, engineering and clinical development of lead products capable of targeting angiogenesis in-vivo and has been the first in the world to demonstrate that human monoclonal antibodies, specific for a marker of angiogenesis, can efficiently and selectively target the tumor neo-vasculature both in animal models and in cancer patients. At present, Philogen has four promising anti-cancer antibody derivatives and an antibody derivative for the treatment of rheumatoid arthritis in clinical studies. Two registrational studies are in planning. Our Zurich-based daughter company Philochem serving as the R&D unit isolates the most promising candidate products, while in Siena (Italy) the pharmaceuticals are produced according to GMP standards and advanced to clinical trials. Philogen generates revenue from a diversified range of activities, has signed agreements with major pharmaceutical companies and owns a diversified portfolio of international patents.
- Sito Web
-
http://www.philogen.com
Link esterno per Philogen S.p.A.
- Settore
- Fabbricazione di prodotti farmaceutici
- Dimensioni dell’azienda
- 51-200 dipendenti
- Sede principale
- Sovicille, SIENA
- Tipo
- Società privata non quotata
- Data di fondazione
- 1996
Località
-
Principale
Loc. Bellaria, 35
Sovicille, SIENA 53018, IT
-
Loc.Montarioso, 11
Monteriggioni, Siena 53035, IT
Dipendenti presso Philogen S.p.A.
Aggiornamenti
-
Happy to meet you tomorrow!
Philogen management will provide an update during the upcoming Webinar taking place on July 10th, 2024 at 14:00 GMT | 15:00 CET. Please use this link to register to the event: https://lnkd.in/dM9KSQia or contact us at [email protected].
-
Our CEO Dario Neri on Spotify with a podcast on Cancer Research! Don't miss it! https://lnkd.in/ddz8v6uA
Behind the Pharma Curtain: Navigating Drug Trials and Cancer Research with Professor Dario Neri
https://spotify.com
-
Don't miss the interview of our CEO Dario Neri on Corriere della Sera!
-
Learn more about the Phase III PIVOTAL trial results from Prof. Axel Hauschild interviewed at ASCO! https://lnkd.in/dg9A2Wir
Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery
ascopost.com
-
Philogen management will provide an update during the upcoming Webinar taking place on July 10th, 2024 at 14:00 GMT | 15:00 CET. Please use this link to register to the event: https://lnkd.in/dM9KSQia or contact us at [email protected].
-
Happy to attend the Goldman Sachs 45th Annual Global Healthcare Conference tomorrow in Miami!
Philogen is pleased to participate and present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 12, 2024. Tune in to hear the latest update from our CEO and CSO Prof. Dario Neri.
-
Philogen S.p.A. ha diffuso questo post
#ASCO24 | Daromun nei pazienti con #melanoma localmente avanzato. L'intervista completa di Paolo A. Ascierto sul trial PIVOTAL. https://lnkd.in/d6qZxMXq
Melanoma localmente avanzato, quale ruolo per daromun? - OncoInfo
https://oncoinfo.it
-
Philogen S.p.A. ha diffuso questo post
Prof. Axel Hauschild presenting the Daromun Phase III Pivotal trial in melanoma! #ASCO 2024
Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery
ascopost.com
Pagine simili
Sfoglia le offerte di lavoro
Raccolta fondi
Ultimo round
Serie sconosciuta69.460.783,00 USD